Brief: Inhibikase Therapeutics Provides Update To FDA Clinical Hold Of IKT-148009 Programs

Inhibikase Therapeutics

07/12/2022 21:18

Dec 7 (Reuters) - Inhibikase Therapeutics Inc  IKT.O :
    * INHIBIKASE THERAPEUTICS PROVIDES UPDATE TO FDA CLINICAL
HOLD OF
IKT-148009 PROGRAMS
    * INHIBIKASE THERAPEUTICS - RECEIVED FDA CLINICAL HOLD
LETTER IN
REGARDS TO CO'S IKT-148009 PROGRAMS IN PARKINSON'S DISEASE,
MULTIPLE SYSTEM ATROPHY
    * INHIBIKASE THERAPEUTICS - BASIS FOR CLINICAL HOLD INCLUDES
FURTHER EVALUATION OF PK DATA IN PHASE 2A '201' CLINICAL TRIAL
    * INHIBIKASE THERAPEUTICS INC - BASIS FOR CLINICAL HOLD
INCLUDES
JUSTIFICATION SUPPORTING USE OF 200 MG DOSE USED IN PHASE 2A
'201' CLINICAL TRIAL
    * INHIBIKASE - FDA ASKS FOR BETTER UNDERSTANDING OF HOW
TRIAL TO
MONITOR POTENTIAL FOR DETECTING ADVERSE EVENTS THAT COULD AFFECT
PARTICIPANTS VISION
    * INHIBIKASE THERAPEUTICS INC - FDA ASKS FOR BETTER
UNDERSTANDING
OF WHETHER ADVERSE EVENTS IN CLINICAL TRIAL ARE REVERSIBLE
    * INHIBIKASE THERAPEUTICS INC - FDA IS SEEKING ADDITIONAL
SUPPORTIVE INFORMATION FOR SELECTION OF 200 MG DOSE IN '201'
TRIAL

Source text for Eikon:  ID:nPn8T9DBPa 
Further company coverage:  IKT.O